Basic Information
| LncRNA/CircRNA Name | LINCRNA-VLDLR |
| Synonyms | VLDLR-AS1, linc-VLDLR, lincRNA-VLDLR |
| Region | GRCh38_9:2621834-2660053 |
| Ensemble | ENSG00000147852 |
| Refseq | NR_015375 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | hepatocellular carcinoma |
| ICD-0-3 | C22.0 |
| Methods | qPCR, RNAi, Western blot etc. |
| Sample | cell lines (HepG2, Hep3B, PLC/PRF-5, Huh-7) |
| Expression Pattern | up-regulated |
| Function Description | lincRNA-VLDLR (linc-VLDLR) was significantly upregulated in malignant hepatocytes. Exposure of HCC cells to diverse anticancer agents such as sorafenib, camptothecin, and doxorubicin increased linc-VLDLR expression in cells as well as within EVs released from these cells. Incubation with EVs reduced chemotherapy-induced cell death and also increased linc-VLDLR expression in recipient cells. RNAi-mediated knockdown of linc-VLDLR decreased cell viability and abrogated cell-cycle progression. |
| Pubmed ID | 24874432 |
| Year | 2014 |
| Title | Involvement of extracellular vesicle long noncoding RNA (linc-VLDLR) in tumor cell responses to chemotherapy. |
External Links
| Links for LINCRNA-VLDLR | GenBank HGNC NONCODE |
| Links for hepatocellular carcinoma | OMIM COSMIC |